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Background: In the absence of a cure, there has been considerable interest in attempts to prevent or reduce the
progression of age-related macular degeneration (AMD) by targeting particular modifiable risk factors. The aim of
this study was to conduct a cross-sectional survey of the current practice of UK eye care professionals in relation to
advice given on diet and other lifestyle modifications for patients with or at risk of AMD.
Methods: Optometrists and ophthalmologists on the membership databases of professional organisations for the
two professions were invited to participate in an online survey. The survey was open for 12 weeks between July
and September 2012.
Results: A total of 1,468 responses were received (96.3% from optometrists and 3.7% from ophthalmologists). The
response rate of those receiving the invitation was 16.2% (1,414/8735) for optometrists and 6% (54/1460) for
ophthalmologists. A majority of respondents reported that they frequently provide dietary advice to patients with
established AMD (67.9%) and those at risk of AMD (53.6%). Typical advice consisted of a recommendation to eat
plenty of leafy green vegetables and eat more oily fish. The decision to recommend nutritional supplements was
based on the risk of progression to advanced AMD, with approximately 93% of respondents recommending
supplementation in a patient with advanced AMD in one eye. However for the majority, the type of supplement
recommended did not comply with current best research evidence, based on the findings of the Age-related Eye
Disease Study (AREDS). Only one in three optometrists regularly assessed smoking status and advised on smoking
cessation.
Conclusions: Within a large sample of eye care professionals, consisting predominantly of optometrists, who
responded to a cross-sectional survey, there was active engagement in providing nutritional advice to patients with
or at risk of AMD. However, the results demonstrate a need to raise awareness of the evidence underpinning the
use of nutritional supplements together with an increased involvement in targeted smoking cessation.
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Age-related macular degeneration (AMD) is the
leading cause of visual impairment in Western coun-
tries and with an ageing population the numbers of
people affected are projected to rise [1]. Although in
recent years, effective therapeutic interventions have
been developed that can stabilize vision in those
with the neovascular (‘wet’) form of the disease, for
the majority of people affected no treatment is cur-
rently available [2]. In its advanced form, AMD has
significant impact on quality of life and profoundly
limits an individual’s ability to function independ-
ently [3]. As a consequence, there has been a great
deal of interest in the identification and targeting of
modifiable risk factors for AMD for both disease
prevention and to reduce the risk of progression to
advanced AMD [4].
Epidemiological studies have identified a variety of
lifestyle exposures that have been putatively linked to
the development and progression of AMD, including
smoking [5,6] and nutritional factors [7]. Smoking has
been identified as the most consistently reported
modifiable risk factor for the development of AMD
and increasing the risk of progression to advanced
AMD. By contrast, the role of diet and nutritional sup-
plementation is much less clear. Data from observa-
tional studies provide inconsistent evidence for a
protective role of dietary antioxidants [8-10] and re-
sults from randomised controlled trials of nutritional
interventions are less encouraging. There is currently
no evidence from randomised intervention studies to
support the use of nutritional supplements in primary
prevention or to slow progression in patients with
early AMD [11,12], however for populations at a
higher risk of progression to advanced disease, the use
of high dose antioxidant vitamin and zinc supplemen-
tation has been shown to be protective [13,14].
Dietary supplements are widely marketed as a strategy
for AMD prevention and treatment and very little reli-
able information is available to guide the public in mak-
ing the decision as to whether or not to take these
supplements. Eye care practitioners are often in a pos-
ition where they have to provide information and advice
to patients with diagnosed AMD or at risk of developing
the disease, on the benefit of specific nutritional inter-
ventions or other lifestyle changes. However, the quality
of the evidence supporting these measures is variable
and often contradictory, which could lead to a lack of
consistency in the advice given. The primary aim of
the present study was to conduct a cross-sectional sur-
vey of UK optometrists and ophthalmologists to inves-
tigate current practice in relation to the targeting of
modifiable risk factors in AMD. A secondary aim of
the study was to identify the sources of evidence thatpractitioners use to inform their recommendations in
this area.
Methods
The survey was delivered entirely online and was hosted
by Survey Monkey (a US provider of web-based surveys
http://www.surveymonkey.com). An initial version of the
survey was developed by the authors and piloted prior
to issuing the final version An invitation to take part in
the survey was included as a news item in an electronic
newsletter that is sent periodically to members of the
College of Optometrists and an email news bulletin sent
to UK consultant ophthalmologists by the Royal College
of Ophthalmologists. Both newsletters included a hyper-
link to the survey home page. An incentive in the form
of a prize draw for £100 in shopping vouchers was of-
fered to those completing the survey. Ethical approval
for the study was granted by the City University London
School of Health Sciences Research and Ethics Commit-
tee and the research was carried out in compliance with
the Declaration of Helsinki (http://www.wma.net/en/
30publications/10policies/b3/index.html).
The survey consisted of 18 forced choice questions
and one free text question divided into 4 sections:
1. Dietary advice (4 questions): questions in this
section asked if practitioners offered dietary advice
to their patients with diagnosed AMD or those at
risk of AMD, follow-up questions asked about
specific advice from a forced-choice list. The list
included advice to increase consumption of leafy
green vegetables (a rich source of the macular
carotenoid lutein), increased intake of oily fish
(source of omega 3 fatty acids) or both of the above.
A free-text option was provided to specify any
additional dietary advice given.
2. Recommendations on the use of nutritional
supplements (6 questions): these questions were
based on the presentation of 3 case scenarios
presenting patients with varying risk of progressing
to advanced AMD:
a. 55-year old patient with no evidence of AMD but
with one or more parents and/or siblings affected
by AMD
b. 65-year old patient with advanced AMD in one
eye and early AMD in the other
c. 75-year old patient with advanced AMD in both eyesRespondents were firstly asked if they would advise
nutritional supplements for each specified patient and if
so, which supplement they would recommend from a list
provided. The scenarios were chosen to reflect the avail-
able evidence-base on the value of nutritional supple-
mentation in AMD.
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widely available in the UK:
AREDS formula e.g. Bausch & Lomb Preservision
Supplement containing macular carotenoids lutein and
zeaxanthin e.g. Macushield
Supplement containing antioxidant vitamins, lutein and
zeaxanthin e.g. ICaps
Supplement containing omega 3 fatty acids e.g. Ocuvite
Complete
The Age-related Eye Disease Study (AREDS) formula-
tion is the only supplement in the list for which evidence
of effectiveness is available from randomised controlled
trials (RCTs) [14]. The composition and doses of nutri-
ents within each of the specified supplements are given
in Table 1.
3. Smoking and AMD (5 questions): this section
investigated practice in relation to taking a smoking
history, whether practitioners explained to patients
the relationship between smoking and AMD, and
whether they provided advice on smoking cessation.
The final question asked if practitioners took a
patient’s smoking history into account when
recommending nutritional supplements. There is
good evidence that smokers who take beta-carotene
may be at increased risk of developing lung cancer
[15] and therefore it is recommended that current
or past smokers should be advised to use a
supplement that does not contain beta-carotene.
4. Evidence base for nutritional supplement
interventions (4 questions): in this section,






Vitamin C 452 - 125 180
Vitamin E 268 - 50 30
Vitamin A 17.2 - 0.8 -
Vitamin B2 - - 1.4 -
Zinc 69.2 - 20 15
Selenium - - 0.05 -
Manganese - - 2 -
Lutein - 10 10 10
Zeaxanthin - 2 ** 2
Meso-zeaxanthin - 10 - -
Omega 3 fatty acids - - - 500
§ composition in mg, *Formulation equivalent to that used in AREDS., **
specified as Lutein/zeaxanthin 10mg.evidence to support the use of nutritional
supplements in the prevention or treatment of AMD.
The terminology adopted by the GRADE working
group [16] for quality of evidence (high, moderate,
low, very low) was used (see Table 2 for an
interpretation of the GRADE categories). The second
part of this section sought to identify the specific
sources of evidence used by respondents to inform
their views regarding the benefits of supplementation.
The survey was set up such that participants could not
go back to change the answer to any question once it
was submitted. Although respondents could exit the sur-
vey at any time, responses to previously answered ques-
tions were automatically saved.
The survey was open for 12 weeks between July-
September 2012. An email reminder was sent approxi-
mately one week after the initial invitation.
The survey data was downloaded into an Excel spread-
sheet and prepared for analysis. Responses to forced choice
questions were analysed as simple proportions of all valid re-
sponses and where appropriate, according to whether the re-
spondent was an optometrist or an ophthalmologist. Free
text responses were also downloaded, coded and then
assigned to categorical variables by the lead author. The text
files obtained from the free-text responses from optome-
trists and ophthalmologists were also used to generate a vis-
ual representation (‘word cloud’). Word clouds give greater
prominence to words that appear more frequently in the
source text (http://www.wordle.net/).
Statistical analysis of differences between the responses
of optometrists and ophthalmologists was carried out
using a Chi-square test and applying Yates’s correction.
Results
A total of 1,468 (full or partial) responses were received
(1,414 (96.3%) from optometrists and 54 (3.7%) from
ophthalmologists). The invitation to take part in the sur-
vey was delivered via an e-newsletter/electronic bulletin
sent to 8,735 members of the College of Optometrists
and 905 UK consultant ophthalmologists by the RoyalTable 2 Details of the quality of evidence categories in
GRADE
GRADE Descriptor
High Further research is very unlikely to change our confidence in
the estimate of effect
Moderate Research is likely to have an important impact on our
confidence in the estimate of effect and may change the
estimate
Low Further research is very likely to have an important impact
on our confidence in the estimate of effect and is likely to
change the estimate
Very low Any estimate of effect is very uncertain.
Table 4 Recommendations on nutritional supplements in
patients with established AMD or at risk of developing
AMD
Patient scenarios % of respondents
recommending
supplements
55-year old patient with no evidence of
AMD but with one or more parents
and/or siblings affected by AMD
33.6
65-year old patient with advanced AMD
in one eye and early AMD in the other
92.8
75-year old patient with advanced AMD
in both eyes
44.8
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receiving the invitation was 16.2% for optometrists and
6% for ophthalmologists.
Dietary advice
The majority (67.9%) of respondents reported that they
would always (or usually) provide dietary advice to patients
with established AMD, with over half (53.6%) regularly of-
fering advice to those considered to be at risk of AMD
(Table 3). The specific advice given to each group was simi-
lar; with most respondents advising patients to eat plenty
of leafy green vegetables and oily fish at least twice a week.
Free text responses most commonly referred to recommen-
dations on eating coloured fruits and vegetables e.g. yellow
peppers, bilberries and blueberries.
No differences were found between responses for op-
tometrists and ophthalmologists in relation to dietary
advice given.
Recommendations on the use of nutritional supplements
The % of respondents recommending nutritional supple-
ments for different types of patient is given in Table 4 and
the frequency of particular supplement recommendations
is provided in Table 5. The results suggest that the likeli-
hood of a patient being advised to take a supplement is
dependent on their risk of progression to advanced AMD;Table 3 Dietary advice to patients with established AMD
or at risk of AMD
Dietary advice N (%)
Frequency of dietary advice for patients
with established AMD
o Always/most of the time 917 (67.9)
o Sometimes 383 (28.4)
o Never 50 (3.7)
Frequency of dietary advice for patients
considered to be at risk of AMD
o Always/most of the time 719 (53.6)
o Sometimes 526 (39.2)
o Never 97 (7.2)
Dietary advice for patients with established AMD
o Eat plenty of leafy green vegetables 497 (38.3)
o Eat oily fish at least twice per week 3 (0.2)
o Both of the above 652 (50.7)
o Other 140 (10.8)
Dietary advice for patients considered to
be at risk of AMD
o Eat plenty of leafy green vegetables 476 (38.4)
o Eat oily fish at least twice per week 6 (0.5)
o Both of the above 585 (47.2)
o Other 173 (14.0)approximately 34% of respondents reported that they
recommended supplementation for primary prevention in
a patient with a family history of AMD, compared to ap-
proximately 93% for a patient with advanced AMD in one
eye and early AMD in the other. The most commonly
reported supplement for people with or at risk of AMD
was either a preparation containing macular carotenoids
only or one containing lutein and zeaxanthin in combin-
ation with antioxidant vitamins. The supplement used in
the AREDS trial (AREDS formula) was one of the least
likely to be recommended (Table 5). For example, in those
respondents recommending a single supplement, the
AREDS formula was recommended by only 13.5% in the
scenario describing a patient with advanced AMD in one
eye.Table 5 Specific supplement recommendations for each
of the 3 patient scenarios
Supplement recommendations N (%)
55-year old patient with no evidence of AMD but with
one or more parents and/or siblings affected by AMD
o AREDS formula 72 (15.6)
o Supplement containing macular carotenoids 287 (62.1)
o Supplement containing antioxidant vitamins, lutein and
zeaxanthin
291 (63.0)
o Supplement containing omega 3 fatty acids 93 (20.1)
65-year old patient with advanced AMD in one eye and
early AMD in the other
o AREDS formula 348 (27.5)
o Supplement containing macular carotenoids 818 (64.6)
o Supplement containing antioxidant vitamins, lutein and
zeaxanthin
724 (57.2)
o Supplement containing omega 3 fatty acids 262 (20.7)
75-year old patient with advanced AMD in both eyes
o AREDS formula 161 (26.8)
o Supplement containing macular carotenoids 395 (65.8)
o Supplement containing antioxidant vitamins, lutein and
zeaxanthin
340 (56.7)
o Supplement containing omega 3 fatty acids 150 (25.0)
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trists, a sub-analysis comparing responses from optome-
trists and ophthalmologists revealed that the latter were
significantly less likely to recommend supplementation
for primary prevention (only 9.6% of respondents
recommending a supplement for a patient at risk of de-
veloping AMD by virtue of family history compared to
34.6% of optometrists (difference significant p=0.0061)).
However when a supplement was recommended, there
was a greater likelihood that ophthalmologists would
recommend the AREDS formula (Figure 1).
Smoking and AMD
Overall, 32.3% of respondents reported regularly taking
a smoking history in new patients and 21.2% in review
patients. However, a greater proportion (49.4%) indi-
cated that they frequently informed smokers of the link
between smoking and eye disease (Table 6). By contrast,
only a third of respondents regularly advised smokers to
quit. The final question in this section asked if smoking
history was taken into account when recommending nu-
tritional supplements. 70.3% responded positively to this
question.
A sub-analysis of differences between optometrists
and ophthalmologists showed that ophthalmologists
were significantly more likely to take a smoking history
from their patients (Figure 2). Furthermore, 70-80% of
ophthalmology respondents frequently explained the re-
lationship between smoking and eye disease and advised
their patients to quit.
Evidence base for nutritional supplement interventions
The four questions in this section concerned the evi-
dence base for the use of nutritional supplements in
AMD and the sources of evidence used to inform prac-
tice (Tables 7 and 8). The majority of respondents rated
the quality of evidence supporting the use of nutritional
supplements for both prevention and slowing theFigure 1 Frequency of particular supplement recommendations for a
other (** p=0.0001. *p=0.0072).progression of AMD as moderate. Articles in profes-
sional journals and conference presentations were the
most frequently cited sources that have informed practi-
tioner views on the role of nutritional supplements in
AMD. Free text responses also commonly referred to
professional journals as the primary evidence source
with the majority of optometrists specifically mentioning
non-peer reviewed professional magazines e.g. Optom-
etry Today and Optician. A significant proportion
(15.1%) also cited the use of manufacturer’s product lit-
erature as an evidence source. There were numerous ref-
erences to specific supplementation studies, in particular
AREDS (21.3%). Other sources of evidence less fre-
quently reported included: personal experience, univer-
sity undergraduate/postgraduate lectures, talking to
colleagues and literature provided by AMD support
groups.
A visual representation of the free-text responses of op-
tometrists and ophthalmologists is shown in Figures 3 and 4.
Discussion
The current study is the first to systematically investigate
the extent to which UK eye care practitioners provide
advice on modifiable risk factors for AMD. The survey
questions were grouped into sections, covering advice
on nutrition (including recommendations regarding nu-
tritional supplements), attitudes and behaviours of op-
tometrists and ophthalmologists towards smoking
cessation and an exploration of the use of evidence to
inform clinical decision making.
The invitation to participate in the survey was deliv-
ered via electronic newsletters issued by UK professional
bodies for optometry and ophthalmology. Although the
membership database of these organisations reflects the
demographics of these professions, since the survey was
anonymous and personal details of respondents were
not collected, it was not possible to establish if the sam-
ple of people who responded to this survey waspatient with advanced AMD in one eye and early AMD in the
Table 6 Results of responses relating to smoking and eye
disease
Smoking advice N (%)
Frequency of taking a smoking history in new
patients
o Every/most of the time 431 (32.3)
o Sometimes 533 (40.0)
o Rarely/never 369 (27.7)
Frequency of taking a smoking history in review
patients
o Every/most of the time 283 (21.2)
o Sometimes 576 (43.2)
o Rarely/never 474 (35.6)
Frequency of informing smokers of the link between
smoking and eye disease
o Every/most of the time 658 (49.4)
o Sometimes 546 (41.0)
o Rarely/never 129 (9.7)
Frequency of advising patients to stop smoking
o Every/most of the time 449 (33.7)
o Sometimes 539 (40.8)
o Rarely/never 345 (25.9)
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Furthermore, the low response rate from ophthalmolo-
gists means that the survey findings predominantly re-
flect the current practice of optometrists. The response
rate from optometrists is consistent with previous studies,
which have reported response rates in the range 12-28%.
Furthermore, the demographics of those responding to
these surveys have been consistent with the national regis-
ter of optometrists in terms of age and gender and geo-
graphic location [17-19]. However, it is possible that those
who responded to the present survey had a particular
interest in AMD. It is difficult to be sure what effect this
would have on the results but it is most likely that theFigure 2 Frequency of taking a smoking history in new patients. (*p=frequency of reporting advice on nutrition and lifestyle is
overestimated rather than underestimated in this survey.
However, we think it unlikely that the information on type
of supplement recommended would be affected by re-
sponse bias.
Approximately two thirds of respondents reported that
they frequently offered dietary advice to those with
established AMD and over half in those considered to
be at risk. Advice given most often consisted of a recom-
mendation to consume plenty of leafy green vegetables.
The rationale behind dietary modification in AMD is
principally to increase the intake of antioxidant nutrients
and more specifically to raise levels of the macular carot-
enoids, lutein and zeaxanthin. Lutein and zeaxanthin are
the principal components of macular pigment which
plays an important role in visual function and also pos-
sesses essential antioxidant and protective blue-light fil-
tering properties [20]. These macular carotenoids are
not synthesised by the body de novo and therefore
humans rely solely on dietary intake. The richest sources
of lutein and zeaxanthin are from leafy green vegetables,
such as spinach and kale, and orange or yellow fruits
and vegetables. Randomised intervention trials investi-
gating the impact of diet on AMD are uncommon and
often target single nutrients. Consequently, the evidence
for the role of diet in AMD is based largely on observa-
tional studies and is therefore subject to confounding
and bias. However, until better quality evidence be-
comes available, it appears that UK eye care practi-
tioners have taken the view that a recommendation to
eat more leafy green vegetables and increase omega 3
fatty acid intake is beneficial, with minimal possibility
of harm. This view is also consistent with current pro-
fessional guidance [21,22].
For certain individuals, it may be difficult to obtain ad-
equate levels of antioxidants and other essential nutri-
ents through diet alone. In such cases, there could be
some advantage in augmenting particular nutrients0.0002).
Table 8 Sources of evidence informing practitioner views
on nutritional supplements and AMD
Sources of evidence (%)
Free text response n = 1,196
o Articles in professional journals 40.2
o Conference presentations, CE events 25.9
o Reference to specific studies e.g. AREDS 21.3
o Scientific/Research literature 16.4
o Manufacturers Literature 15.0
o Expert opinion 11.7
o Cochrane Reviews 0.8
o Medline 0.8
o NICE guidance 0.3
o Other 18.6
Responses to forced choice question n=1,245
o Articles in professional journals 88.4
o Expert opinion 46.1
o Conference presentations 62.9
o NICE guidance 23.1
o Medline 7.7
o Cochrane Reviews 5.7
o None of the above 2.3
Abbreviations: CE=Continuing education, NICE= National Institute for Health
and Clinical Excellence, AREDS=Age-related Eye Disease Study.
Table 7 Results of responses rating the quality of
evidence supporting the use of nutritional supplements
in AMD
Quality of evidence N (%)
Rating of the strength of evidence supporting the use
of supplements for AMD prevention
o High quality 185 (13.9)
o Moderate quality 873 (65.6)
o Low quality 247 (18.6)
o Very low quality 25 (1.9)
Rating of the strength of evidence supporting the use
of supplements for slowing the progression of AMD
o High quality 215 (16.2)
o Moderate quality 849 (64.1)
o Low quality 239 (18.0)
o Very low quality 22 (1.7)
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of supplementation in AMD comes primarily from the
AREDS trial [13], which demonstrated that a supple-
ment containing high doses of vitamin C, vitamin E,
beta-carotene and zinc could reduce progression to ad-
vanced AMD by 25% in populations with intermediate
AMD or advanced AMD in one eye. The present survey
presented three scenarios of patients with varying de-
grees of risk of progression to advanced AMD along
with a question asking whether they would recommend
a supplement and if so, which one from a supplied list.
The results demonstrated that the decision to recom-
mend supplementation was based on the likelihood of
disease progression, with approximately 93% of respon-
dents reporting that they would recommend a supple-
ment in a person with advanced AMD in one eye and
early AMD in the other. However, despite the availability
of evidence from the AREDS trial that this category of
patient would benefit from a formulation containing
high dose vitamins and zinc (AREDS formula), this par-
ticular supplement was one of the least likely to be
recommended. Instead, the majority of respondents
reported that they advised patients to take a supplement
containing macular carotenoids only or a product
containing lutein and zeaxanthin in combination with
antioxidant vitamins. However, the latter typically con-
tain lower doses of antioxidant vitamins than found in
the AREDS formula.
Approximately 96% of survey responses were received
from optometrists and therefore the pooled data primar-
ily reflects the practice of optometrists. However, a sub-
analysis of ophthalmologist responses showed significant
differences in the type of supplement recommended.
Specifically, for the scenario describing a patient with
advanced AMD in one eye and early AMD in the other,
the AREDS formula was the most likely to berecommended by ophthalmologists (approximately 70% of
selections), compared to only 26% by optometrists. Al-
though it is possible that this discrepancy is due to re-
sponse bias, the magnitude of the difference suggests a
different approach to supplementation by the two profes-
sions. A possible explanation is that many optometrists
may be unaware of the evidence-base supporting the use
of the AREDS formula. However, from the optometrist’s
free-text responses to the question asking about evidence
sources used to inform decision making, it was clear that
there was a high level of awareness of the AREDS trial,
which could explain the large number of respondents who
recommended supplementation in a patient at high risk of
AMD progression. However, this awareness did not trans-
late into recommending an AREDS-type supplement. An-
other possible explanation is that optometrists may have
chosen an alternative supplement due to the potential for
adverse reactions associated with the AREDS formula.
There have been well-publicised concerns regarding the
use of supplements containing doses of vitamins and min-
erals that are significantly higher than the recommended
daily allowance (RDA).
It is important that any advice given to patients regard-
ing lifestyle modifications and particularly recommenda-
tions on the benefits of nutritional supplementation is
informed by the best available research evidence. The
Figure 3 Word cloud generated from free-text responses from optometrists (N=1,196) to a question asking about sources of evidence
used to inform recommendations on the use of nutritional supplements.
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were lectures or conference presentations and articles in
professional journals. Large numbers of optometrist
respondents referred specifically to professional ‘maga-
zines’ that are produced either weekly or fortnightly
and contain non peer-reviewed clinical articles. It may
also be of significance that these periodicals frequently
contain featured articles sponsored by manufacturers
and advertisements for a variety of alternative nutri-
tional products.
Most research concerning the evidence-based practice
and information-seeking behaviour of healthcare profes-
sionals has focussed on nurses and doctors. However, a
systematic review examining factors which determine
the application of research evidence by allied health pro-
fessionals, identified level of academic qualification, in-
volvement in research and practitioners attitudes and
beliefs about evidence based practice as significant pre-
dictors of the use of research evidence in practice [23].
With regard to the specific use of evidence by optome-
trists, although a recent. Australian study found gener-
ally positive attitudes towards evidence-based practice,
most practitioners reported a reliance on information
gained during undergraduate or postgraduate training or
continuing education courses to inform their clinical
decision-making [24].Figure 4 Word cloud generated from free-text responses from ophth
evidence used to inform recommendations on the use of nutritionalIn addition to the well documented harmful effects of
smoking on the cardiovascular and respiratory systems,
there is increasing evidence that smoking is causally
linked to the development of AMD [25]. Smoking in-
creases the risk of AMD two-fold and based on the UK
population, it has been estimated that approximately
28,000 cases of AMD in older people may be directly at-
tributable to smoking [26]. Since public awareness of the
link between smoking and ocular health is lacking
[27-29], eye care professionals play a critical role in edu-
cating the public and encouraging smokers to quit.
However, only a third of respondents in the current sur-
vey reported that they regularly took a smoking history
in new patients and a similar number were proactive in
advising on smoking cessation. Previous studies that
have investigated the attitudes and practice of optome-
trists in this area have reported similar findings [30,31].
These studies also identified a number of barriers to
routinely addressing a patient’s smoking behaviour in-
cluding time constraints and a perceived need for fur-
ther training in this area [31].
A sub-analysis of ophthalmologist responses suggests
that this profession may be more likely to take a smok-
ing history and encourage patients to quit. The percent-
age of respondents who reported that they regularly
checked on smoking status in the current survey (70%)almologists (N=47) to a question asking about sources of
supplements.
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larger sample of UK ophthalmologists [32], which could
reflect a either a change in awareness over time or re-
sponse bias.
Conclusions
There are a number of inherent design limitations of the
current study. The overwhelming majority of respondents
were optometrists and consequently the reported practices
predominantly reflect that of optometrists. Furthermore, the
low response rate increases the potential for selection bias,
which may have impacted on the reported practices and
views expressed. Despite these limitations, the results sug-
gest that many UK eye care professionals are actively en-
gaged in providing nutritional advice to patients with or at
risk of AMD.
Although supplements are commonly recommended for
those at greater risk of progression to advanced disease,
the results of the present study indicated that the majority
of supplement recommendations do not comply with
current available evidence. Furthermore, since smoking has
been identified as a consistent risk factor for the develop-
ment and progression of AMD, the results also suggest
that the assessment of smoking status and the provision of
targeted support to quit could be substantially improved. A
Cochrane review [33] has confirmed that a brief smoking
cessation intervention consisting of simple advice by physi-
cians increases the likelihood that a smoker will success-
fully quit. By combining such advice with awareness-
raising of the link between smoking and AMD, eye care
professionals could potentially provide an additional stimu-
lus for smokers to quit. The results of the present study
highlight the need for profession-specific guidance to sup-
port lifestyle interventions for AMD.
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